Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

397.27 +0.63 (+0.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,203,148
Open 395.72
Bid (Size) 394.00 (2)
Ask (Size) 395.35 (2)
Prev. Close 396.64
Today's Range 386.49 - 401.31
52wk Range 377.85 - 519.88
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?
Via The Motley Fool

Performance

YTD
-3.32%
-3.32%
1 Month
-11.91%
-11.91%
3 Month
-13.64%
-13.64%
6 Month
-16.36%
-16.36%
1 Year
-2.55%
-2.55%

More News

Read More
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
Via Investor's Business Daily
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
The Ultimate Biotech Stock to Buy With $500 Right Now
Via The Motley Fool
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Via Benzinga
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain
Via Investor's Business Daily
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Via Investor's Business Daily
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Unstoppable Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Via The Motley Fool
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Via Benzinga
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
Via Benzinga
2 No-Brainer Stocks to Buy Before the End of 2024
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.